LONDON – In January 2023, the US FDA granted mRNA-1345 Breakthrough Therapy Designation for the prevention of RSV-LRTD in adults aged 60 years or older, and mRNA-1345 was previously granted Fast Track designation by the U.S. FDA in August 2021.“We’ve seen the impact that respiratory viruses like RSV can have on the health and wellbeing of Canadians. As we approach …